Genetic Engineering & Biotechnology News spoke with our CEO, Tamer Mohamed, to learn about Aspect's microfluidic 3D bioprinting technology and how it's being applied.
“We’re the first and only group in the world to marry microfluidics to 3D printing and apply the combination to generate bioprinted therapeutics. Our technology platform enables us to take a rational-design, first-principles approach to building implantable biological therapies.” - Tamer Mohamed, CEO, Aspect Biosystems
Read the article here.
Source: The article was originally published on Genetic Engineering & Biotechnology News on April 2, 2021.Back to all